Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Optical genome mapping (OGM) is a new genome-wide technology that can reveal both
structural genomic variations (SVs) and copy number variations (CNVs) in a single assay …

Cytogenetics has long represented a critical component in the clinical evaluation of
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …

Although venous thromboembolism (VTE) is an important treatment and disease-related
complication in myeloma, a validated risk prediction model including disease-specific …

Multiple myeloma (MM) is an acquired malignant plasma cell disorder that develops late in
life. Although progression free and overall survival has improved across all age, race, and …

The multiple myeloma treatment landscape has changed dramatically. This change,
paralleled by an increase in scientific knowledge, has resulted in significant improvement in …

Aims Cytogenetic abnormalities involving the IGH gene are seen in up to 55% of patients
with multiple myeloma. Current testing is performed manually by fluorescence in situ …

Background Multiple myeloma (MM) is a highly heterogeneous disease with enormously
variable outcomes. It remains to be a major challenge to conduct a more precise estimation …

Multiple myeloma is a plasma cell neoplasm driven by primary (eg hyperdiploidy; IGH
translocations) and secondary (eg 1q21 gains/amplifications; del (17p); MYC translocations) …

Cytogenomic analyses of acquired clonal chromosomal abnormalities in neoplastic blood,
bone marrow, and/or lymph nodes are instrumental in the clinical management of patients …